BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9805	Companies
196647	Keywords
127661	Articles
104550	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 02/19/2025 at 09:10, 11 months 13 days ago

BioNxt Solutions se lance dans une étape stratégique de 90 jours

Solutions BioNxt Dépôts De Brevets Systèmes D'administration De Médicaments Marché Anti-âge Essais Cliniques Sur La Sclérose En Plaques
PRESS RELEASE

published on 02/19/2025 at 09:05, 11 months 13 days ago

BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
BioNxt Solutions Inc. announces major milestones for the next 90 days, including global patent filings, bioequivalence study for MS treatment, and expansion into longevity & anti-aging sector

BioNxt Solutions Inc. Patents Longevity Anti-Aging Bioequivalence Study
BRIEF

published on 01/21/2025 at 09:10, 1 year ago

BioNxt's Strategic Move to Gen-Plus Laboratory in Munich

Pharmaceutical Innovation R&D Expansion BioNxt Solutions Drug Delivery Systems Gen-Plus Laboratory
BRIEF

published on 01/21/2025 at 09:10, 1 year ago

Déménagement stratégique de BioNxt vers le laboratoire Gen-Plus à Munich

Innovation Pharmaceutique Solutions BioNxt Systèmes D'administration De Médicaments Laboratoire Gen-Plus Expansion De La R&D
PRESS RELEASE

published on 01/21/2025 at 09:05, 1 year ago

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
BioNxt Solutions Inc. relocates R&D activities to Gen-Plus CRDO in Munich, Germany, enhancing capabilities and fostering collaborations in drug delivery systems, neurodegenerative therapeutics, and biomedical tech

BioNxt Solutions Inc. Munich R&D Activities Drug Delivery Systems Gen-Plus CRDO
BRIEF

published on 12/19/2024 at 09:10, 1 year 1 month ago

BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations

Multiple Sclerosis BioNxt Solutions Sublingual Delivery Patent Expansion Drug Innovation
BRIEF

published on 12/19/2024 at 09:10, 1 year 1 month ago

BioNxt Solutions élargit son portefeuille de brevets pour ses innovations en matière d'administration de médicaments

Sclérose En Plaques Innovation Pharmaceutique Solutions BioNxt Extension Du Brevet Administration Sublinguale
PRESS RELEASE

published on 12/19/2024 at 09:05, 1 year 1 month ago

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
BioNxt Solutions Inc. expands its intellectual property portfolio with new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. The company aims to bring patient-friendly therapies to individuals affected by these diseases

BioNxt Solutions Inc. Intellectual Property Patents Autoimmune Neurodegenerative Diseases Sublingual Delivery Technologies
BRIEF

published on 12/09/2024 at 09:10, 1 year 1 month ago

BioNxt Solutions Advances BNT23001 for MS Treatment

Clinical Trials Drug Development Multiple Sclerosis BioNxt Solutions BNT23001
BRIEF

published on 12/09/2024 at 09:10, 1 year 1 month ago

BioNxt Solutions développe le BNT23001 pour le traitement de la sclérose en plaques

Essais Cliniques Sclérose En Plaques Développement De Médicaments Solutions BioNxt BNT23001

Accesswire

Published on 02/05/2026 at 01:35, 2 hours 44 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 4 hours 19 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 5 hours 54 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 10 hours 19 minutes ago

Lithium South AGSM Update
Published on 02/04/2026 at 16:15, 12 hours 4 minutes ago

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 20:54, 7 hours 25 minutes ago

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 7 hours 43 minutes ago

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 8 hours 19 minutes ago

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 9 hours 24 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 9 hours 39 minutes ago

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology

Les Echos

Published on 02/04/2026 at 18:04, 10 hours 15 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 10 hours 15 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 10 hours 34 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 10 hours 34 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 10 hours 34 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE